Description: Introduction; R.E. Poupon. Section I: General Considerations on Surrogate Markers. 1. Surrogate Markers in AIDS Clinical Trials; J.-P. Aboulker. 2. Surrogate Markers and Prediction of Cardiovascular Disease; P.W.F. Wilson. 3. Requirements for Surrogate Markers as Seen by Regulatory Agencies; C. Peck. Section II: Scores and Quantitative Tests. 4. Quantitative Liver Function Tests; N. Tygstrup. 5. The Threshold Hypothesis of Sodium Retention in the Presence of Liver Disease Provides a Surrogate Marker for the Onset of Ascites; R.A. Branch. 6. Scores in Different Diseases. A Critical Review and Evaluation of Different Surrogate Markers for Assessing Treatments in Chronic Liver Disease; E. Christensen, M.R. Schunk. 7. Validation of Surrogate Markers for Death in Cirrhosis: an Example Using Decrease in Galactose Elimination Capacity; C. Merkel, et al. 8. Quantitative Liver Function Tests as Surrogate Markers for End Points in Controlled Clinical Trials; E. Lotterer, et al. Section III: Cirrhosis and Portal Hypertension. 9. The Child-Turcotte and Chilf-Pugh Classifications; N. McIntyre. 10. Portal Hypertension and Survival; J. Bosch, et al. 11. Impact of Ascites on Survival of Patients with Liver Cirrhosis; M. Bernardi, et al. Section IV: New and Old Markers. 12. Serum Markers for Liver Fibrosis - Current and Future Developments; D. Schppan, et al. 13. Surrogate Markers to Assess Efficiency of Treatment in Chronic Liver Diseases: New Biochemical Indices; G. Ramadori, F. Polzien. 14. Liver Biopsy as a Surrogate Marker in Chronic Liver Disease; B. Portmann. 15. Measurement of Quality of Life; A.J. Chwalow. 16. Surrogate Markers: Quality of Life in Liver Disease; H.U. Fisch, et al. Section V: Chronic Liver Disease. 17. Assessment of Treatment in Cholestasis; U. Beuers, G. Paumgartner. 18. Hepatic Uptake and Excretion of Bile Acids: Quantitative Tests of Liver Function in Chronic Cholestatic Liver Diseases; R.P. Jazrawi, et al. 19. Surrogate Markers to Assess Efficacy of Treatment in Chronic Liver Diseases: Viral Hepatitis; L. Pagliario, et al. 20. Surrogate Markers in Chronic Liver Diseases &e Essence from the Poster Session; J. Scholmerich. Concluding Remarks; J. Reichen. Index.

Please Wait